Breaking News

THERAVECTYS Plant Gains Mfg. Status from ANSM

Fully operational to supply comprehensive immunotherapeutic treatments

Author Image

By: Kristin Brooks

Managing Editor, Contract Pharma

THERAVECTYS’ manufacturing plant has obtained the status of a pharmaceutical manufacturing establishment, granted by the French National Agency for Medicines and Health Products Safety (ANSM). The new facility will produce lentiviral vectors for clinical development from Phase I through Phase III, and will also be used to manipulate human cells for chimeric antigen receptors (CARs) and t-cell receptor (TCR)-based cell therapies.   The company is now fully operational to supply comprehensiv...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters